Suppliers / HEC Pharm

HEC Pharm

China 135 employees reconciled across 13 public records · 6 entities Updated 9 July 2026

HEC Pharm is an API and finished-dose manufacturer based in China. It holds 43 active US drug master files and 4 valid CEPs. Its filings concentrate with AEMPS (ES), US FDA and EMA. Its GMP standing is certified by EMA, US FDA and ZLG (DE). Its most recent recorded inspection, by US FDA, closed on 22 November 2024 as NAI.

43
active US DMFs
4
valid CEPs
9
registered plants 5 with an FDA FEI number
109
filings across 8 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 22 November 2024 NAI US FDA
  • 31 May 2024 NAI US FDA
  • 29 November 2019 VAI US FDA
  • 11 September 2015 NAI US FDA
  • 26 March 2015 NAI US FDA
  • 4 May 2011 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Yidu City, China Not on file
China, China 3018718574
Yidu, China Not on file
China, China 3009740510
Shaoguan City, Ruyuan County, Guangdong Province, China Not on file
China, China 3015516273

3 further sites are on record.

What they file, and where

Molecule Regulators Docs
Clarithromycin SFDA (Saudi Arabia), US FDA 4
Erythromycin US FDA 4
Sitagliptin SFDA (Saudi Arabia), US FDA 4
Azithromycin SFDA (Saudi Arabia), US FDA 3
Entacapone EDQM, US FDA 3
Escitalopram US FDA 3
Moxifloxacin EDQM, US FDA 3
Olanzapine EDQM, US FDA 3
Atorvastatin US FDA 2
Azilsartan Medoxomil US FDA 2
Show all 40 molecules on file
Duloxetine US FDA 2
Esomeprazole US FDA 2
Febuxostat US FDA 2
Fingolimod SFDA (Saudi Arabia), US FDA 2
Levofloxacin US FDA 2
Lincomycin US FDA 2
Metoprolol US FDA 2
Olmesartan US FDA 2
Rosuvastatin US FDA 2
Tenofovir Disoproxil US FDA 2
Ticagrelor US FDA 2
Zidovudine US FDA 2
Alogliptin US FDA 1
Apixaban US FDA 1
Apremilast US FDA 1
Aripiprazole US FDA 1
Brivaracetam US FDA 1
Finerenone US FDA 1
Linagliptin US FDA 1
Linagliptin And SFDA (Saudi Arabia) 1
Moxifloxacin Hydrochloride EDQM 1
Oseltamivir US FDA 1
Prasugrel US FDA 1
Ritonavir US FDA 1
Rivaroxaban US FDA 1
Sofosbuvir SFDA (Saudi Arabia) 1
Solifenacin Succinate US FDA 1
Sugammadex US FDA 1
Tadalafil US FDA 1
Vonoprazan US FDA 1

Also appears on these molecule pages

Show 10 more molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
AEMPS (ES) 41 None
US FDA 35 2
EMA 27 9
MPA (SE) 5 None
ARCSA (EC) 3 None
JFDA (JO) 3 None
ZLG (DE) None 2

Questions about HEC Pharm

Does HEC Pharm hold a US DMF or a CEP?
HEC Pharm holds 43 active US drug master files and 4 valid CEPs. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is HEC Pharm FDA-registered?
5 sites operated by HEC Pharm carry an FDA establishment identifier (FEI), which means they are registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did HEC Pharm's last inspection go?
The most recent inspection on record closed on 22 November 2024 as NAI (No Action Indicated: nothing objectionable was found). 6 inspections are on file.
Where does HEC Pharm manufacture?
9 registered sites are on record, in China, Germany and United States (Yidu City, China and Yidu among others). Every site is listed on this page with the register it came from.
What does HEC Pharm make?
40 molecules are on record against HEC Pharm, including Clarithromycin, Erythromycin, Sitagliptin and Azithromycin. Each links through to that molecule's full manufacturer list.
Which regulators recognise HEC Pharm's GMP?
Current GMP certificates are on record from EMA, US FDA and ZLG (DE). GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. HEC Pharm comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 5 active litigation matters are on record.
  • The most recent inspection outcome was NAI, on 22 November 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates